Table 2. Table depicting accessibility of checkpoint inhibitors from 2015 to 2019.
| Disease site | Years | 2015 | 2016 | 2017 | 2018 | 2019 | p-value |
|---|---|---|---|---|---|---|---|
| Head and neck cancer | Number of patients with indication for immunotherapy | - | 776 | 773 | 750 | 1136 | <0.001 |
| Number of patients who received immunotherapy | - | 2 | 27 | 43 | 84 | ||
| Percentage of patients receiving immunotherapy | - | 0.25 | 3.49 | 5.7 | 7.3 | ||
| 95% CI of the percentage of patients receiving immunotherapy | - | 0.01–1 | 2.4-5.1 | 4.3–7.7 | 6–9.1 | ||
| Thoracic cancer | Number of patients with indication for immunotherapy | 1,365 | 1,844 | 2,730 | 3,000 | 3,300 | <0.001 |
| Number of patients who received immunotherapy | 1 | 3 | 44 | 110 | 130 | ||
| Percentage of patients receiving immunotherapy | 0.07 | 0.16 | 1.6 | 3.6 | 3.9 | ||
| 95% CI of the percentage of patients receiving immunotherapy | 0–0.4 | 0.03–0.5 | 1.2–2.1 | 3.1–4.4 | 3.3–4.7 |